Search Results

October 10, 2014

Janssen Submits Application Seeking Approval Of Stelara® In European Union For Pediatric Plaque Psoriasis

October 10, 2014

New Findings From The Psoriasis Longitudinal Assessment And Registry (Psolar) Show Persistency Difference Among Biologic Therapies

Persistence of STELARA® (ustekinumab) Significantly Better than Anti-TNFs in Treatment of Psoriasis According to Observational Study Analysis

Corporate

May 22, 2015

STELARA® Receives CHMP Positive Opinion For Treatment Of Adolescents With Moderate To Severe Psoriasis In Europe

STELARA Recommended for Approval in Paediatric Patients 12 Years and Older with Moderate to Severe Psoriasis

Corporate

April 28, 2015

Janssen Launches U.S. Hispanic Community Initiative to Help Improve Type 2 Diabetes Care

New research shows marked differences between Hispanic and non-Hispanic type 2 diabetes patients in disease perceptions and management approaches, highlighting need for tailored education among patients and healthcare professionals

Medical technologies

May 22, 2014

Johnson & Johnson Medical Devices & Diagnostics Businesses Expanding Market Leadership with Innovative Products and Customer-Focused Solutions

More than 30 major product filings planned through 2016 Leading the industry in emerging market sales

Innovative Medicine

March 24, 2014

Anti-Interleukin-23 Monoclonal Antibody Guselkumab Shows Significant Efficacy In Treatment Of Moderate To Severe Plaque Psoriasis

Results from Phase 2b X-PLORE Study through Week 40 Report Efficacy of Guselkumab across Multiple Dosing Regimens and Compared with Adalimumab

Corporate

May 18, 2015

New Real-World Data Show Adults with Type 2 Diabetes, Including Those Taking Multiple Diabetes Medications, Achieve Blood Glucose Treatment Goals After Using INVOKANA®(canagliflozin)

Findings Also Show Some Patients Discontinue Use of Other Blood-Glucose-Lowering Medications after Initiation of INVOKANA®

Innovative Medicine

November 7, 2016

Late-Breaking Results from XARELTO® PIONEER AF-PCI Study Among 18 New Studies Accepted for Presentation at the American Heart Association Scientific Sessions 2016

Innovative Medicine

June 13, 2016

Janssen Presents New Data Showing INVOKANA® (canagliflozin) is Associated with Greater Blood Glucose Control and Treatment Adherence Compared to DPP-4 Inhibitors

Other Presentations at American Diabetes Association Scientific Sessions® Show INVOKANA® Therapy also is Associated with Achieving Blood Glucose and Blood Pressure Treatment Goals

Medical technologies

January 22, 2013

Johnson & Johnson Presents Growth Strategies for Medical Devices & Diagnostics Segment

Search Results

No Results

Recently Viewed

Search Results